COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2

Overview of attention for article published in eClinicalMedicine, January 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 16 X users

Readers on

mendeley: 48 Mendeley

So far, Altmetric has seen 22 X posts from 16 X users, with an upper bound of 32,134 followers.

2%にゅういん https://t.co/zuJNm7UFgN

自己増殖RNAの英国治験『201人のうち、12 人が重度以上の有害事象を経験しました。12 人のうち 4 人は入院を必要とする重篤な有害事象 (心筋虚血、脛骨骨折、良性副甲状腺腫瘍、変形性関節症) 』論文より https://t.co/CoQEj4h5nT

RT @CumberpatchM: @ermagosh131 @IamBrookJackson The UK was involved in phase 2 studies in 2020 https://t.co/p0nFgHbeQo

@ermagosh131 @IamBrookJackson The UK was involved in phase 2 studies in 2020 https://t.co/p0nFgHbeQo

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 18 additional X posts.